Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022 at 11:35 AM EDT
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Signs Off Marker ...